CLINICAL ROLE -
Trilaciclib Protects Against Chemotherapy-Induced Myelosuppression
Treatment's approval marks exciting new development for patients with ES-SCLC to prevent CIM.
Help Manage Toxicities With BRAF and MEK Inhibitors
Watch for alopecia, arthralgia, diarrhea, fatigue, nausea, pyrexia, rash, and vomiting, among others.
FDA Approves Newest Antibody-Drug Conjugate for Cervical Cancer
Tisotumab vedotin-tftv is used as antitumor therapy for patients with disease progression during or after chemotherapy.
Calls Grow for Treatment Deintensification of HPV-Positive OPC
Clinicians cite long-term complications and younger patients with better prognoses as reasons to pull back on oropharyngeal cancer therapy.
Immunotherapy Revolutionizes Treatment of ES-SCLC
Addition of atezolizumab and durvalumab to chemotherapy is a win for patients with extensive-stage small cell lung cancer
2 Commerce Drive Cranbury, NJ 08512